Romosozumab in Postmenopausal Women with Low Bone Mineral Density
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. METHODS: In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the three sites). Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months (140 mg or 210 mg), subcutaneous placebo, or an open-label active comparator--oral alendronate (70 mg weekly) or subcutaneous teriparatide (20 μg daily). The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Secondary end points included percentage changes in bone mineral density at other sites and in markers of bone turnover. RESULTS: All dose levels of romosozumab were associated with significant increases in bone mineral density at the lumbar spine, including an increase of 11.3% with the 210-mg monthly dose, as compared with a decrease of 0.1% with placebo and increases of 4.1% with alendronate and 7.1% with teriparatide. Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-formation markers and sustained decreases in a bone-resorption marker. Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse events were similar among groups. CONCLUSIONS: In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the simultaneous, acute increase in P1NP and reduction in CTx that we observed in the T3 group is qualitatively identical (but smaller in magnitude) to the effects of sclerostin inhibition on bone markers in humans22, and arguably pathognomonic of the consequences of sclerostin inhibition on bone.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
In the citing paper
“the time course of changes in bone formation we observed over 20 weeks of intermittent D + Q treatment in the T3 group is virtually identical (albeit smaller in magnitude) to that observed following treatment with the FDA-approved sclerostin inhibitor, romosozumab, where serum P1NP increased rapidly over the first 1–4 weeks following dosing and then returned to baseline by 24 weeks22.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442
Cited by
Items 901–1,000 of 1,000
INTENZO, C. M., Parker, L., Levin, D. C., Kim, S. M., & Rao, V. M. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.10.001 · Cited by 3
Nuevas terapias en osteoporosis
Posada, A. F., Aguirre, H. D., Casallas, J. C. G., Patiño, J. D. L., & Valle‐Oñate, R. (2016) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2015.12.010 · Cited by 3
Jiang, Q., Zhang, F., Zhu, B., Zhang, H., Han, L., & Liu, X. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-1294 · Cited by 4
Wang, D., & Wang, H. (2022) · Physiology · doi:10.5772/intechopen.101803 · Cited by 6
Garnero, P., & Cremers, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00078-6 · Cited by 9
Brandi, M. L., & Medio, L. D. (2020) · Endocrinology · doi:10.1007/978-3-030-14782-2_19 · Cited by 3
Hayashi, K. (2023) · Drugs - Real World Outcomes · doi:10.1007/s40801-023-00385-z · Cited by 3
Pereira, R. C., Noche, K. J., Gales, B., Chen, Z., Salusky, I. B., & Albrecht, L. V. (2024) · Children · doi:10.3390/children11070820 · Cited by 3
The genome as pharmacopeia: Association of genetic dose with phenotypic response
Wadhawan, S., Runz, H., & Burchard, J. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.02.005 · Cited by 3
Effects of anti-sclerostin antibody and running on bone remodeling and strength
Toumi, H., Benaîtreau, D., Pallu, S., Mazor, M., Hambli, R., Ominsky, M. S., & Lespessailles, É. (2015) · Bone Reports · doi:10.1016/j.bonr.2015.03.002 · Cited by 6
Anabolic and Catabolic Pathways of Parathyroid Hormone on the Skeleton
Silva, B. C. C., & Bilezikian, J. P. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397166-1.00015-1 · Cited by 3
CORR Insights®: Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model?
Holguin, N. (2016) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-016-4697-3 · Cited by 3
Actualités du traitement de l’ostéoporose post-ménopausique
Briot, K., & Roux, C. (2015) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2015.11.008 · Cited by 3
Osteoblasts as leukemia-initiating cells
Frisch, B. J., & Calvi, L. M. (2014) · BoneKEy Reports · doi:10.1038/bonekey.2014.67 · Cited by 3
Serum sclerostin levels in renal cell carcinoma patients with bone metastases
Wibmer, C., Amrein, K., Fahrleitner‐Pammer, A., Gilg, M. M., Berghold, A., Hutterer, G. C., Maurer-Ertl, W., Gerger, A., Leithner, A., Pichler, M., et al. (2016) · Scientific Reports · doi:10.1038/srep33551 · Cited by 3
Gaffney‐Stomberg, E., MacArthur, M. R., & McClung, J. P. (2016) · Exposure and Health · doi:10.1007/978-94-007-7745-3_27-1 · Cited by 3
3D Local in vivo Environment (LivE) imaging for single cell protein analysis of bone tissue
Taylor, C., Scheuren, A. C., Trüssel, A. J., & Müller, R. (2016) · Current Directions in Biomedical Engineering · doi:10.1515/cdbme-2016-0099 · Cited by 3
Bone biology in the elderly: clinical importance for fracture treatment
Rolvien, T., & Amling, M. (2016) · Innovative Surgical Sciences · doi:10.1515/iss-2016-0025 · Cited by 4
Pregnancy, Lactation, and Bone Health
Miedany, Y. M. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-87950-1_28 · Cited by 3
Genotypic and Clinical Analysis of a Thalassemia Major Cohort: An Observational Study
Tsartsalis, A. N., Lambrou, G. Ι., Samartzi, A., Vlachou, E. D., Papassotiriou, I., Geronikolou, S. A., Kanaka‐Gantenbein, C., Chrousos, G. P., & Kattamis, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-78787-5_10 · Cited by 3
Swinney, D. C. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108175 · Cited by 3
Gutgesell, R. M., Jamshed, L., Frank, R., Hewitt, L. M., Thomas, P. J., & Holloway, A. C. (2022) · Journal of Applied Toxicology · doi:10.1002/jat.4370 · Cited by 4
Bone Biology and Effects of Pharmaceutical Intervention on Bone Quality
Ott, S. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802792-9.00002-1 · Cited by 5
Commentary on Sclerostin Deficiency Is Linked to Altered Bone Composition
Eriksen, E. F. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2346 · Cited by 3
Osteoporosis therapeutics: recent developments at ASBMR
Mallarkey, G., & Reid, D. M. (2016) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x15623489 · Cited by 3
Therapy for musculoskeletal disorders
Gasser, J. A. (2016) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2015.12.001 · Cited by 3
How different is the once-weekly teriparatide from the daily one or the same?
Takeuchi, Y. (2019) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2019.06.004 · Cited by 3
Lifelong genetically lowered sclerostin and risk of cardiovascular diseasePreprint
Bovijn, J., Krebs, K., Chen, C., Boxall, R., Censin, J. C., Ferreira, T. D. G. M., Pulit, S. L., Glastonbury, C. A., Laber, S., Millwood, I. Y., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/531004 · Cited by 3
In Vivo quantification of 4D modeling and remodeling in trabecular and cortical bone microstructure
Shyu, P. T., Robinson, S. T., & Guo, X. (2025) · Frontiers in Medical Engineering · doi:10.3389/fmede.2025.1547895 · Cited by 2
Mikula, A. L., Choy, W., Pennington, Z. A., Semonche, A. M., Wozny, T. A., Mazur-Hart, D. J., Kim, J., Nguyen, T. H., Clark, A., Deviren, V., et al. (2025) · Journal of Neurosurgery Spine · doi:10.3171/2025.1.spine241325 · Cited by 3
Risk factors and reasons for romosozumab nonadherence in a case-control study
Tsai, T.-C., Yen, Y.-S., Lin, C.-H., Cheng, Y.-C., Ding, Y.-S., Chiang, C.-H., & Wu, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-04595-z · Cited by 5
Nusrat, S., Din, R. U., Tariq, M. A., & Yang, H. (2025) · The Journal of Gene Medicine · doi:10.1002/jgm.70031 · Cited by 2
Goshima, A., Tsuboi, H., Kaito, T., & Iwasaki, M. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf141 · Cited by 2
Mesinovic, J., Ryan, J. R., Ng, C., Zengin, A., Ebeling, P. R., & Scott, D. A. H. (2025) · Bone · doi:10.1016/j.bone.2025.117656 · Cited by 2
Medvedeva, E. V., Ivanov, N. V., Vesnina, A. F., Хромова, Е. А., & Yusupova, S. K. (2025) · Obstetrics Gynecology and Reproduction · doi:10.17749/2313-7347/ob.gyn.rep.2025.678 · Cited by 3
Keaveny, T. M., Oates, M. K., Betah, D., Shi, Y., Timoshanko, J., Lee, D. C., Bydon, M., Krohn, K., & Ishikawa, K. (2025) · The Spine Journal · doi:10.1016/j.spinee.2025.10.032 · Cited by 2
Research Status and Hot Spot Visualization Analysis of Osteoporosis from 2014 to 2025
Huang, Y., Wang, F., Lian, K., Li, L., & Wang, Z. (2025) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s541592 · Cited by 2
Geusens, P., Hul, W. V., van den Bergh, J. P., & Lems, W. F. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2594642 · Cited by 2
Lu, K.-H., Wang, S., & Yang, S.-F. (2026) · Biology of Sex Differences · doi:10.1186/s13293-025-00817-1 · Cited by 2
3 months of romosozumab: a pragmatic clinical solution
Khosla, S. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00323-7 · Cited by 2
Richardson-Thornton, I., Brennan, S., Liu, L., Streeter, C., Hill, J. L., Clifton-Bligh, R., Girgis, C., & Gild, M. (2026) · Osteoporosis International · doi:10.1007/s00198-025-07808-3 · Cited by 2
The effect of prior osteoporosis treatment on bone mineral density response to romosozumab
Ta, B., Ho, F. C. W., Bliuc, D., Chen, W., & Sheu, A. (2026) · Bone · doi:10.1016/j.bone.2026.117892 · Cited by 2
AlShamsi, H., Alnaqbi, D., Sharma, C., Govender, R. D., & Almazrouei, R. A. (2026) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514261440728 · Cited by 2
Yukishima, T., Kobayakawa, T., Hirano, Y., Kanayama, Y., Niimi, R., Etani, Y., Noguchi, T., Noguchi, T., Shimoyama, K., Maekawa, Y., et al. (2026) · Osteoporosis International · doi:10.1007/s00198-026-08051-0 · Cited by 2
Tsujino, S., Koyanagi, H., Sawamura, C., Tozuka, K., & Gokita, T. (2026) · Archives of Osteoporosis · doi:10.1007/s11657-026-01724-7 · Cited by 2
Romosozumab in postmenopausal women with classical Osteogenesis imperfecta
Bartosik, M., Windels, O., von Brackel, F. N., Amling, M., & Oheim, R. (2026) · Archives of Osteoporosis · doi:10.1007/s11657-026-01744-3 · Cited by 2
Novel antibody therapy demonstrates potential for building bone in osteoporosis
Heath, V. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.1 · Cited by 2
Neue Antiosteoporotika am Horizont
Knauerhase, A., & Willenberg, H. S. (2016) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-016-0102-6 · Cited by 2
Osteoporosis en enfermedades reumáticas e inducidas por glucocorticoides
Maldonado, G., Messina, O. D., Moreno, M., & Ríos, C. (2017) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2017000100007 · Cited by 9
Li, X., Asuncion, F., Ominsky, M. S., Niu, Q., Åkesson, K., Wang, J. C., Lieberman, J. R., & Ke, H. Z. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.06.019 · Cited by 3
Role of sclerostin, fibroblast growth factor-23, and Klotho in hemodialysis patients
Elmenyawi, A. I., & Hassan, A. (2019) · Journal of Medicine in Scientific Research · doi:10.4103/jmisr.jmisr_84_18 · Cited by 2
Biochemical Markers of Bone Turnover
Greenblatt, M. B., Tsai, J. N., & Wein, M. N. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_9 · Cited by 2
The Role of Novel Bone Forming Agents in the Treatment of Osteoporosis
Patel, H. B., Lyerly, L. J., & Horlen, C. K. (2020) · Journal of Pharmacy Practice · doi:10.1177/0897190020961227 · Cited by 2
Chitosan based bionanocomposites in osteoporosis
Niranjan, M. K., Baghel, K., & Azam, Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821280-6.00014-3 · Cited by 2
Romosozumab: A Novel Agent in the Management of Osteoporosis
Moon, N. H., Shin, W. C., & Jang, J. H. (2021) · Journal of the Korean Fracture Society · doi:10.12671/jkfs.2021.34.4.148 · Cited by 2
Rauner, M., & Hofbauer, L. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-34238-2_1 · Cited by 4
Effects of Digestive Diseases on Bone Metabolism
Sylvester, F. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-67293-1.00091-8 · Cited by 2
Sclerostin immunohistochemical staining in surgically treated giant cell tumor of bone
Kelly, S. P., Ramkumar, D. B., Peacock, Z. S., Newman, E. T., Venrick, C. B., Lozano‐Calderón, S. A., Raskin, K. A., Chebib, I. A., & Schwab, J. H. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.26903 · Cited by 2
Mathur, A. S., Gopalakrishnan, D., Sharath, S., Mehta, V., Bagwe, S., & Kumbhalwar, A. (2024) · Journal of Datta Meghe Institute of Medical Sciences University · doi:10.4103/jdmimsu.jdmimsu_235_20 · Cited by 2
RetractedOsteoporosis in Pregnant and Lactating Females: An Update
Mishra, N., Masroor, H., & Gupta, M. (2024) · Turkish Journal of Osteoporosis · doi:10.4274/tod.galenos.2023.24392 · Cited by 2
Prevalence of fractures in adults over 50 years of age with osteoporosis in Colombia
Correa-González, N., Fernández-Ávila, D. G., & Rosselli, D. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01412-4 · Cited by 2
Arrieta, L. A. R., Galvis, P. A. R., Galvis, M. V. R., Meneses, S. A. P., Rodriguez, J. M. Y., & Contreras, F. J. S. (2025) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2025_05719 · Cited by 2
Singh, M., Sabharwal, S., Jamwal, N., Gupta, M., & Garg, K. (2025) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_108_25 · Cited by 2
Vía de señalización Wnt en artritis reumatoide
Giraldo, R. B., Santos, A. M., & Londoño, J. D. (2015) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2015.04.001 · Cited by 5
Control of Bone Homeostasis by the Wnt Inhibitor Sclerostin
McGee‐Lawrence, M. E., & Hamrick, M. W. (2016) · Current Molecular Biology Reports · doi:10.1007/s40610-016-0040-8 · Cited by 3
Civitelli, R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00079-0 · Cited by 3
Fulzele, K. S., & Pajevic, P. D. (2017) · Current Molecular Biology Reports · doi:10.1007/s40610-017-0061-y · Cited by 2
Biology of Bone and the Interaction of Bone with Other Organ Systems
Findlay, D. M. (2017) · Courses and lectures · doi:10.1007/978-3-319-58845-2_6 · Cited by 2
Vitamin D Activities in Osteocytes
Anderson, P., Atkins, G. J., Morris, H. A., & Findlay, D. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809965-0.00019-7 · Cited by 2
Stress and Insufficiency Fractures
Shaker, J. L. (2017) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-017-9239-3 · Cited by 2
The high bone mass phenotype of Lrp5-mutant mice is not affected by megakaryocyte depletion
Yorgan, T. A., David, J., Amling, M., & Schinke, T. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.127 · Cited by 2
Individualisierte Therapie der Osteoporose
Harbeck, B., & Lehnert, H. (2016) · Der Internist · doi:10.1007/s00108-016-0074-2 · Cited by 2
Effects of locally applied Insulin-like Growth Factor-I on osseointegration
López-Quiles, J., Forteza-López, A., Montiel, M., Clemente, C., Fernández-Tresguerres, J., & Tresguerres, I. F. (2019) · Medicina oral, patología oral y cirugía bucal · doi:10.4317/medoral.22973 · Cited by 2
Disuse osteoporosis: A better understanding of pathophysiology may lead to potential therapies
Milsom, S. R., Sy, L., Cornish, J., & Sharma, S. (2016) · Journal of Diabetology and Endocrinology · doi:10.14312/2398-0281.2016-1 · Cited by 2
Individualisierte Therapie der Osteoporose
Harbeck, B., & Lehnert, H. (2016) · rheuma plus · doi:10.1007/s12688-016-0089-8 · Cited by 2
How Basic Science Discoveries Have Shaped the Treatment of Bone and Mineral Disorders
Langdahl, B. L., & Ralston, S. H. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3316 · Cited by 2
Self-citationPharmacologic basis of sclerostin inhibition
Ke, H. Z., Roberts, S. J., & Holdsworth, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00074-9 · Cited by 2
Medical and Metabolic Considerations in Athletes With Stress Fractures
Schwartz, E. N., & Edmondson, C. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-54942-4.00004-x · Cited by 2
Gold, D. T. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00082-0 · Cited by 2
Falls and Osteoporosis Post-Stroke
Dockery, F., & Sommerville, P. (2015) · Springer eBooks · doi:10.1007/978-3-319-17855-4_11 · Cited by 2
Development of Novel Models for Studying Osteoclasts
Thudium, C. S. (2014) · Lund University Publications (Lund University) · Cited by 4
Compliance with osteoporosis medications – an underestimated determinant of anti-fracture efficacy
Anagnostis, P. G., & Karras, S. Ν. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1027186 · Cited by 2
Rendina-Ruedy, E. (2015) · SHAREOK (University of Oklahoma; Oklahoma State University; Central Oklahoma University) · doi:10.13140/rg.2.1.5090.3208 · Cited by 2
Lv, F., Cai, X., & Ji, L. (2020) · Bone · doi:10.1016/j.bone.2020.115271 · Cited by 2
Bone-forming agents in non-responders to bisphosphonates
Compston, J. E. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31824-x · Cited by 1
Histomorphometry of Remodeling and Modeling-Based Mineral Apposition
Li, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-5613-2_4 · Cited by 2
Clinical research–When it matters
Yao, M., Wang, H., & Chen, W. (2022) · Injury · doi:10.1016/j.injury.2022.01.049 · Cited by 1
Efficacy and Cardiovascular Safety of Romosozumab: A Meta-analysis and Systematic Review
Choi, S.-Y., Kim, J., Oh, S.-H., Cheon, S., & Chung, J. E. (2023) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2023.33.2.128 · Cited by 1
Impact of romosozumab treatment for 24 months after switching from denosumab: three case reports
Ahn, S. H., Lee, S., Lee, S. H., Kim, H. Y., Hong, S., & Koh, J. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf070 · Cited by 1
Montazeri‐Najafabady, N., Mokarram, P., & Dastghaib, S. (2025) · Journal of Cellular Biochemistry · doi:10.1002/jcb.70055 · Cited by 1
EndoCompass Project: Research Roadmap for Calcium and Bone Endocrinology
Jähn, K., Tomšić, K. Z., Anastasilakis, A. D., Bertocchio, J., Brandi, M. L., Faßnacht, M., Cheung, M., Gevers, E. F., Gittoes, N. J. L., Mäkitie, O., et al. (2025) · Hormone Research in Paediatrics · doi:10.1159/000549160 · Cited by 1
Chiang, M.-H., Fan, T.-S., Lee, C., Tseng, T.-H., Yen, H., Hung, C., Lu, Y.-C., Sie, N.-H., Wang, C., & Fu, S. (2025) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2025.11.002 · Cited by 1
Kao, W.-H., Yang, Y.-S., Lan, C.-L., Lo, W., Chiang, Y. H., & Lin, J.-H. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07813-6 · Cited by 1
Self-citationNagashio, S., Sakai, H., Kondo, E., & Umehara, A. (2025) · Journal of Oral and Maxillofacial Surgery Medicine and Pathology · doi:10.1016/j.ajoms.2025.10.015 · Cited by 1
Ricciardi, G., Donadio, D., Ficarra, G., Nasso, C., Foglia, P., Bitto, A., Scarfì, R., Fadda, G., Corpina, F., Cutè, E., et al. (2026) · Bone · doi:10.1016/j.bone.2026.117801 · Cited by 1
Romosozumab for the treatment of thalassemia-associated osteoporosis in two female patients
Yavropoulou, M. P., Koloutsou, M. E., Delaporta, P., Makras, P., Anastasilakis, A. D., Kassi, E., Kattamis, A., & Xekouki, P. (2026) · JBMR Plus · doi:10.1093/jbmrpl/ziag020 · Cited by 1
Yukishima, T., Kobayakawa, T., Hirano, Y., Kanayama, Y., Niimi, R., Etani, Y., Noguchi, T., Shimoyama, K., Maekawa, Y., Nakata, K., et al. (2026) · Rheumatology · doi:10.1093/rheumatology/keag082 · Cited by 2
Current outlook on the use of monoclonal antibody therapies for osteoporosis
Almohaya, M. S., Almehthel, M. S., & Kendler, D. L. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2641051 · Cited by 1
Romosozumab is effective in patients with variants in LRP5, LRP6, or WNT1
von Brackel, F. N., Dehne, N., Kornak, U., Barvencik, F., Schinke, T., Amling, M., & Oheim, R. (2026) · Osteoporosis International · doi:10.1007/s00198-026-07932-8 · Cited by 1
Naqvi, S., Ali, W., Allison, H., O’Sullivan, L., Holdsworth, G., Pérez, J. A. P., Schiavi, J., & McNamara, L. M. (2026) · Bone Reports · doi:10.1016/j.bonr.2026.101915 · Cited by 1
Metadata
- Authors
- McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., Katz, L., Maddox, J., Yang, Y.-C., Libanati, C., & Bone, H. G.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Amgen (United States) (US)
- KU Leuven (BE)
- National Institutes of Health (US)
- Centre hospitalier universitaire de Québec (CA)
- Aarhus University Hospital (DK)
- University of Liège (BE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-30
- Volume
- 370
- Issue
- 5
- Pages
- 412-420
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096627331
- Cited by
- 1,258
- References
- 16
- Citations by year
- 2026: 75 · 2025: 97 · 2024: 82 · 2023: 52 · 2022: 99 · 2021: 93 · 2020: 121 · 2019: 69 · 2018: 90 · 2017: 105 · 2016: 125 · 2015: 139 · 2014: 101
- FWCI
- 160.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- romosozumab, sclerostin, postmenopausal osteoporosis, osteopenia, bone mineral density, bone formation, bone resorption, alendronate, teriparatide, osteocytes, osteoblast activity, monoclonal antibodies, dose comparison, injection site reactions
- MeSH terms
- Aged, Aged, 80 and over, Antibodies, Monoclonal, Calcium, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Lumbar Vertebrae, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Least-Squares Analysis, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.